Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Dr. Reddy’s Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Dr. Reddy’s Laboratories Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17
Dr. Reddy’s Labs Acquires Six OTC Brands from Ducere Pharma 19
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20
Dr Reddy’s Labs Acquires Brands Portfolio of UCB for USD128 Million 21
Dr Reddy’s Labs Acquires Habitrol from Novartis Consumer Health 22
Dr Reddy’s Labs Plans To Acquire Drug Brands In Latin America 23
Private Equity 24
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24
Partnerships 26
Dr. Reddy’s Laboratories Enters into Distribution Agreement with UCB 26
Department of Science & Technology Enters into Agreement with Dr Reddy’s Labs, University of Hyderabad and Dr Reddy’s Institute of Life Sciences 27
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 28
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29
CutisPharma Partners with Dr. Reddy’s Labs 30
Dr. Reddy’s Labs Enters into Agreement with TR-Pharm 31
Dr. Reddy’s Labs Enters into Distribution Agreement with Biocodex 32
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen 33
Purdue University Enters into MoU with Dr Reddy’s Labs 34
Dr Reddy’s Labs Enters into Distribution Agreement with Astrazeneca Pharma 35
Dr Reddy’s Labs Plans to Enter into Agreement 36
Aurigene Discovery Enters into Agreement with Curis 37
Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy’s Laboratories 39
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40
Licensing Agreements 41
Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42
Dr. Reddy’s Labs Enters into Licensing Agreement with Eisai for E7777 43
Dr. Reddy’s Labs Enters into Licensing Agreement with XenoPort for XP23829 44
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45
Dr. Reddy’s Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47
Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy’s Labs 48
Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy’s Labs For NeuVax 52
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53
Dr. Reddy’s Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54
Dr Reddy’s Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55
Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56
Equity Offering 57
Octoplus Completes First Tranche Of Private Placement Of Common Stock For US$1.6 Million 57
Asset Transactions 58
Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy’s Laboratories 58
EPI Health Acquires Rights of Cloderm from Promius Pharma 59
Genomma Lab Acquires Bufferin Brand from Dr. Reddy’s Labs 60
Acquisition 61
Neopharma Acquires Dr. Reddy’s Laboratories Tennessee from Dr. Reddy’s Laboratories 61
Dr Reddy’s Labs Acquires OctoPlus 62
Dr. Reddy’s Laboratories Ltd – Key Competitors 64
Dr. Reddy’s Laboratories Ltd – Key Employees 65
Dr. Reddy’s Laboratories Ltd – Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Joint Venture 68
Recent Developments 69
Financial Announcements 69
Oct 26, 2018: Dr. Reddy’s Q2 & H1 FY19 financial results 69
Jul 26, 2018: Dr. Reddy’s Q1 FY19 financial results 70
May 22, 2018: Dr. Reddy’s Q4 and FY18 Financial Results 72
Jan 25, 2018: Dr. Reddy’s Q3 and 9M FY18 Financial Results 74
Oct 31, 2017: Dr. Reddy’s Q2 and H1 FY18 Financial Results 76
Jul 27, 2017: Dr. Reddy’s Q1 FY18 Financial Results 77
May 12, 2017: Dr. Reddy’s Q4 and FY17 Financial Results 78
Feb 04, 2017: Dr. Reddy’s Q3 and 9M FY17 Financial Results 80
Corporate Communications 82
Oct 25, 2018: Dr. Reddy’s Laboratories: Appointment of Mr. Leo Puri as an Additional Director, categorjzed as Independent, on the Board of the Company 82
Jun 14, 2018: Dr. Reddy’s Announces Resignation of Hans Peter Hasler As Independent Director 83
Mar 29, 2018: Dr. Reddy’s Laboratories announces Senior Leadership Changes 84
Oct 30, 2017: Dr Reddys Laboratories appoints Prasad R Menon as an Additional Director 85
Legal and Regulatory 86
Oct 30, 2018: Dr Reddy’s slips 7% following 8 USFDA observations for Duvvada plant 86
Aug 23, 2018: Dr. Reddy’s Laboratories: Update on audit of API Srikakulam Plant, Andhra Pradesh 87
Jun 28, 2018: Dr. Reddy’s Laboratories: Update on Audit of its API Hyderabad Plant 3 and API Hyderabad Plant 1 88
Jun 28, 2018: Indivior’s Temporary Restraining Order is Extended 89
Jun 03, 2018: Dr Reddy’s API Srikakulam plant gets USFDA nod 90
Jun 02, 2018: Dr. Reddy’s Laboratories Provides Update on US FDA Inspection of its API Srikakulam Plant 91
Apr 24, 2018: Dr. Reddy’s Laboratories Provides Update on US FDA Inspection of its API Plant in Mirfield, UK 92
Mar 16, 2018: Dr. Reddy’s Provides Update on Update on USFDA Audit of its API Hyderabad Plant at Medak,Telangana 93
Feb 25, 2018: Dr. Reddy’s Laboratories Provides Update on USFDA Audit of its API Manufacturing Plant at Srikakulam, India 94
Feb 19, 2018: Dr Reddy’s Laboratories: Update on US Lawsuit 95
Jan 24, 2018: Dr. Reddy’s Laboratories: Intimation regard to Communication from Betapharm Arzneimittel, Germany from the Regulatory Authority of Germany 96
Jan 22, 2018: Dr. Reddy’s fined $5mn by US court over drug packaging 97
Dec 19, 2017: Dr. Reddy’s announces it has reached a settlement with the US Government regarding company’s compliance with the Consumer Product Safety Act 98
Dec 11, 2017: Dr. Reddys announced audit of formulations manufacturing plant 99
Dec 01, 2017: Dr. Reddy’s Laboratories: Intimation regard to the US FDA audit 100
Nov 21, 2017: Dr. Reddy’s Laboratories: Intimation regarding receipt of EIR 101
Sep 21, 2017: Dr. Reddys Announced audit of custom Pharmaceutical Services Facility 102
Sep 21, 2017: Dr. Reddy’s Laboratories: Intimation about audit of Srikakulam Plant Unit II, Andhra Pradesh, by the US FDA 103
Sep 15, 2017: Dr. Reddy’s Laboratories: Intimation about audit of API Mirfield Plant, United Kingdom, by the US FDA 104
Sep 08, 2017: Dr. Reddy’s Laboratories: Regulatory Authority of Germany concludes audit of Formulations manufacturing facility in Vishakapatnam, India 105
Sep 08, 2017: Dr. Reddy’s Laboratories Announces Intimation on audit 106
Jul 21, 2017: Dr. Reddy’s Laboratories: Update On US FDA Audit at API Cuernavaca Plant 107
Jun 16, 2017: Dr. Reddy’s Laboratories: Update on USFDA Audit 108
Jun 14, 2017: Dr. Reddy’s Provides Update on API manufacturing plant at Miryalaguda 109
May 25, 2017: Dr. Reddy’s Laboratories Provides Update on Srikakulum Plant 110
Apr 28, 2017: Dr. Reddy’s Provides Update On US FDA Audit At Bachupally Plant 111
Apr 14, 2017: Dr. Reddy’s Provides Update on USFDA Audit 112
Apr 03, 2017: Dr. Reddy’s Laboratories Provides Update on USFDA Inspection at Srikakulam plant 113
Feb 21, 2017: Dr. Reddy’s Laboratories Announces US FDA Inspection on Miryalaguda Facility 114
Product News 115
12/01/2017: Dr. Reddy’s Announces Approval of Impoyz (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval 115
Aug 28, 2017: Dr. Reddy’s Laboratories Breathes New Life into Doan’s in New Marketing Campaign 116
Jun 03, 2018: Dr Reddy’s expects to launch over 15 products in US in FY’19 117
Jan 17, 2018: Dr Reddy’s recalls over 1,000 vials of cancer drug from US 118
Clinical Trials 119
Feb 07, 2018: Armis Biopharma to Present at the BIO CEO & Investor Conference 119
Jan 29, 2018: Armis Biopharma Granted QIDP for Lead Product, Ximycin for Prophylaxis of Surgical Site Infections in High-Risk Patients Undergoing Non-Emergent Colorectal Surgery 120
Other Significant Developments 121
Feb 08, 2017: Dr. Reddy’s Expands Commercial Operations in Europe 121
Appendix 122
Methodology 122
About GlobalData 122
Contact Us 122
Disclaimer 122
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Dr. Reddy's Laboratories Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 17
Dr. Reddy’s Labs Acquires Six OTC Brands from Ducere Pharma 19
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 20
Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 21
Dr Reddy's Labs Acquires Habitrol from Novartis Consumer Health 22
Dr Reddy's Labs Plans To Acquire Drug Brands In Latin America 23
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 24
Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 26
Department of Science & Technology Enters into Agreement with Dr Reddy’s Labs, University of Hyderabad and Dr Reddy’s Institute of Life Sciences 27
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 28
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 29
CutisPharma Partners with Dr. Reddy's Labs 30
Dr. Reddy's Labs Enters into Agreement with TR-Pharm 31
Dr. Reddy’s Labs Enters into Distribution Agreement with Biocodex 32
Dr. Reddy’s Labs Enters into Distribution Agreement with Amgen 33
Purdue University Enters into MoU with Dr Reddy's Labs 34
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 35
Dr Reddy's Labs Plans to Enter into Agreement 36
Aurigene Discovery Enters into Agreement with Curis 37
Shenzhen Foncoo Pharmaceutical Enters into Agreement with Dr. Reddy's Laboratories 39
Dr. Reddy’s Labs Enters Into Co-Development Agreement With Merck Serono For Biosimilars 40
Encore Dermatology Enters into Licensing Agreement with Promius Pharma 41
Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 42
Dr. Reddy's Labs Enters into Licensing Agreement with Eisai for E7777 43
Dr. Reddy's Labs Enters into Licensing Agreement with XenoPort for XP23829 44
Curis Exercises Option for Licensing Agreement with Aurigene Discovery 45
Dr. Reddy’s Labs Enters into Licensing Agreement with PanTheryx for DiaResQ 47
Taxus Cardium Pharma Enters into Licensing Agreement with Dr. Reddy's Labs 48
Dr. Reddy Labs Enters into Licensing Agreement with Spectrum Pharma 49
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 50
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 51
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 52
Curis Exercises Option for Licensing Agreement with Aurigene Discovery for CA-327 53
Dr. Reddy’s Labs Enters into Agreement with Hatchtech for Xeglyze Lotion 54
Dr Reddy's Labs Enters into Licensing Agreement with Hetero Drugs for Sofosbuvir 55
Promius Pharma Enters into Licensing Agreement with CMP Pharma for Trianex 56
Octoplus Completes First Tranche Of Private Placement Of Common Stock For US$1.6 Million 57
Therapiva to Acquire API Manufacturing Business Unit from Dr. Reddy's Laboratories 58
EPI Health Acquires Rights of Cloderm from Promius Pharma 59
Genomma Lab Acquires Bufferin Brand from Dr. Reddy’s Labs 60
Neopharma Acquires Dr. Reddy's Laboratories Tennessee from Dr. Reddy's Laboratories 61
Dr Reddy's Labs Acquires OctoPlus 62
Dr. Reddy's Laboratories Ltd, Key Competitors 64
Dr. Reddy's Laboratories Ltd, Key Employees 65
Dr. Reddy's Laboratories Ltd, Subsidiaries 66
Dr. Reddy's Laboratories Ltd, Joint Venture 68
List of Figures
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Dr. Reddy's Laboratories Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Dr. Reddy's Laboratories Ltd, Medical Devices Deals, 2012 to YTD 2018 13